

Transition-Metal-Free Intermolecular α -C-H Amination of Ethers at Room Temperature

*Ivan Buslov and Xile Hu**

Laboratory of Inorganic Synthesis and Catalysis
Institute of Chemical Sciences and Engineering
Ecole Polytechnique Fédérale de Lausanne (EPFL)
ISIC-LSCI, BCH 3305, Lausanne 1015 (Switzerland)
E-mail: xile.hu@epfl.ch

Supporting information

Content	Page
1. Chemicals and Reagents 2. Physical methods 3. General procedures for the entries reported in Table 1	S2
4. The procedures for the preparation of starting materials	S3
5. General procedures for the intermolecular α -C-H amination of ethers	S4
6. Mechanistic studies	S5
7. Detailed descriptions of the products	S7
8. References	S21
9. NMR spectra	S22

Experimental Section

1. Chemicals and Reagents

All manipulations were carried out under an inert N₂(g) atmosphere using standard Schlenk or glovebox techniques. Solvents were purified using a two-column solid-state purification system (Innovative Technology, NJ, USA) and transferred to the glove box without exposure to air. Deuterated solvents were purchased from Cambridge Isotope Laboratories, Inc., and were degassed and stored over activated 3 Å molecular sieves. THF-d₈ was purchased from ARMAR AG, and was degassed and stored over activated 3 Å molecular sieves. Unless otherwise noted, all other reagents and starting materials were purchased from commercial sources and used without further purification. Liquid compounds were degassed by standard freeze-pump-thaw procedures prior to use. Tetrahydropyran and 2-methyltetrahydrofuran were distilled from stabilizers before use. Dry 1,2-dimethoxyethane was purchased from Aldrich and used without purification. Diphenyl iodonium hexafluorophosphate and triflate were purchased from ABCR and Aldrich correspondently. 2,2-Dimethylpent-4-en-1-amine was synthesized according to literature procedure.¹ Other amines were purchased from commercial sources. Sulfonamides², amides and trifluoroacetyl amides³ were prepared from corresponding amines by standard methods. 3-(4-methoxybenzyl)-5-methylpyrimidine-2,4(1H,3H)-dione⁴ and di-tert-butyl 5-fluoro-2,4-dioxypyrimidine-1,3(2H,4H)-dicarboxylate⁵ were prepared according to known procedures.

2. Physical methods

The ¹H and ¹³C NMR spectra were recorded at 293 K or 373 K on Bruker Avance 400 spectrometers. ¹H NMR chemical shifts were referenced to residual solvent as determined relative to Me₄Si (δ = 0 ppm). The ¹³C{¹H} chemical shifts were reported in ppm relative to the carbon resonance of CDCl₃ (77.16 ppm), DMSO-d₆ (39.52 ppm), CD₂Cl₂ (53.84 ppm) or CD₃CN (118.26 ppm). GC measurement was conducted on a Perkin-Elmer Clarus 400 GC with a FID detector. HRESI-MS measurements were conducted at the EPFL ISIC Mass Spectrometry Service with a Micro Mass QTOF Elemental analyses were performed on a Carlo Erba EA 1110 CHN instrument at EPFL.

3. General procedures for the entries reported in Table 1

Entries 1-10, 18-20

Sodium hydride (60% dispersion in mineral oil, 10 mg, 0.25 mmol, entries 1-7) or corresponding base (0.25 mmol, entries 8-10) was added to a stirred solution of N-benzylmethanesulfonamide (46 mg, 0.25 mmol) in 1 mL of dry tetrahydrofuran at room temperature under nitrogen. After stirring for 1 hour an oxidant (0.3 mmol) was added slowly and the reaction mixture was left stirred for 10 hours. In entry 5 no oxidant was added; instead a balloon with O₂ was connected to reaction vessel. After the indicated time, the reaction mixture was analyzed by GCMS using 30 µL of dodecane as an internal standard.

Entries 11-17

Sodium hydride (60% dispersion in mineral oil, 10 mg, 0.25 mmol) was added to a stirred solution of N-benzylmethanesulfonamide (46 mg, 0.25 mmol) and dry tetrahydrofuran (0.18 g, 2.5 mmol) in 1 mL of the corresponding solvent at room temperature under nitrogen. After stirring for 1 hour Ph₂IPF₆ (128 mg, 0.3 mmol) was added and the reaction mixture was left stirred for 10 hours.

4. The procedures for the preparation of starting materials

General procedure for the preparation of sulfonamides (1a-1m)

To a stirred solution of primary amine (20 mmol) and pyridine (2.37 g, 30 mmol) in CH_2Cl_2 (50 mL) at 0°C a corresponding sulfonyl chloride (20 mmol) was slowly added. The reaction mixture was slowly warmed to room temperature and stirred for 12 hours, then the reaction was quenched with water (30 mL), extracted with CH_2Cl_2 (2x50 mL) and washed with water. The organic phase was dried over anhydrous Na_2SO_4 . The solvent was evaporated to afford the product. If needed, crude product was purified by silica gel flash chromatography using mixture of ethylacetate/hexane as an eluent.


General procedure for the preparation of N-acetamides (2a-2d, 2i-2o)

20 mmol of the corresponding amine was dissolved in 50 mL of CH_2Cl_2 followed by the addition of triethylamine (3.03 g, 30 mmol) and dropwise addition of acetyl chloride (1.72 g, 22 mmol) at 0°C . After stirring for 10 hours at room temperature 30 mL of water was added to the reaction solution. The organic phase was separated and aqueous layer was extracted two times with 50 mL of chloroform, and the resulting organic layer was concentrated after drying with anhydrous Na_2SO_4 to obtain the product. If needed, crude product was purified by silica gel flash chromatography using mixture of ethylacetate/hexane as an eluent.

General procedure for the preparation of N-trifluoroacetamides (2e-2h)

20 mmol of the corresponding amine and pyridine (2.37 g, 30 mmol) were dissolved in 50 mL of dry CH_2Cl_2 . Trifluoroacetic anhydride (22 mmol 4.62 g) in 20 mL of CH_2Cl_2 was added slowly at 0°C . The reaction was stirred overnight at room temperature, quenched with water, extracted twice with CH_2Cl_2 and washed with water. The organic layers were dried with Na_2SO_4 , and the solvent was evaporated. The residue was purified by silica gel flash chromatography using mixture of hexane/ethyl acetate as an eluent.

Tert-butyl 5-fluoro-2,6-dioxo-3,6-dihydropyrimidine-1(2H)-carboxylate (9b)



5-Fluorouracil (3.9 g, 30.0 mmol), di-tert-butyl dicarbonate (26.2 g, 120 mmol), pyridine (5 mL), DMAP (100 mg, 0.8 mmol) and MeCN (50 mL) were stirred together for 12 h at room temperature. The reaction mixture was concentrated in vacuo, and the residue was partitioned between CH_2Cl_2 (100 mL) and water (100 mL). The organic layer was separated, and the aqueous phase was extracted twice with CH_2Cl_2 (2x50 mL). The combined organic layers were dried over MgSO_4 and filtered, and the solvent was removed by evaporation in vacuo. The residue was purified by recrystallization from Hexane-EtOAc (10:1) to afford 6.70 g (68%) of di-tert-butyl 5-fluoro-2,4-dioxypyrimidine-1,3(2H,4H)-dicarboxylate (**9b'**).

Purified **9b'** (330 mg, 1 mmol) was dissolved under argon in 2 mL of dry THF. A 1 M solution of Bu₄NF (1.5 mL, 1.5 mmol) in THF was then added and the reaction mixture was refluxed for 8 h. After cooling to room temperature, water (20 mL) was added. After extraction with AcOEt (2×20 mL), the organic layers were washed with brine (10 mL), dried with Na₂SO₄, filtered and the solvent was removed under reduced pressure. The crude product was purified by gradient silica gel chromatography (hexane/AcOEt 10:1 to 1:1) to afford N3-Boc-5-fluorouracil as white powder 87 mg (38%).

5. General procedures for the intermolecular α -C-H amination of ethers

General procedure for the synthesis of N-(tetrahydrofuran-2-yl)sulfonamides (3a-3n)

To a suspension of sodium hydride (60% dispersion in mineral oil, 20 mg, 0.5 mmol) in 1 mL of dry THF a sulfonamide (0.5 mmol) in 1 mL of THF was added at room temperature under nitrogen. After stirring for 1 hour at room temperature Ph₂IPF₆ (256 mg, 0.6 mmol) was added and the reaction mixture was left stirred for 6 hours. The solvent was removed under reduced pressure and resulting solid was subjected to column chromatography (silica gel) to afford the product. For the new compounds, their ¹H and ¹³C data were reported together with high resolution mass spectrometric data or elemental analysis.

General procedure for the synthesis of N-(tetrahydrofuran-2-yl)amides (5a-5o)

To a suspension of sodium hydride (60% dispersion in mineral oil, 20 mg, 0.5 mmol) in 1 mL of dry THF an amide (0.5 mmol) in 1 mL of THF was added at room temperature under nitrogen. After stirring for 3 hours at room temperature Ph₂IPF₆ (319 mg, 0.75 mmol) in 1 mL of THF was added and the reaction mixture was left stirred for 6 hours. The solvent was removed under reduced pressure and resulting solid was subjected to the column chromatography (silica gel) to afford the product. For the new compounds, their ¹H and ¹³C data were reported together with high resolution mass spectrometric data or elemental analysis.

General procedure for the synthesis of phthalimide derivatives (5p, 8b, 8d)

To a suspension of potassium phthalimide (92.5 mg, 0.5 mmol) in 2 mL of corresponding alkyl ether Ph₂IPF₆ (256 mg, 0.6 mmol) was added and reaction mixture stirred at 40°C or 60°C overnight under nitrogen. The solvent was removed under reduced pressure and resulting solid was subjected to the column chromatography (silica gel) to afford the product.

General procedure for the α -C-H bond amination with N-heterocyclic amines (7a-7d)

To a suspension of sodium hydride (60% dispersion in mineral oil, 20 mg, 0.5 mmol) in 1 mL of dry THF an amine (0.5 mmol) in 1 mL of THF was added at room temperature under nitrogen. After stirring for 1 hour at room temperature Ph₂IPF₆ (319 mg, 0.75 mmol) was added and the reaction mixture was left stirred for 6 hours. The solvent was removed under reduced pressure and resulting solid was subjected to column chromatography (silica gel) to afford the product. For the new compounds, their ¹H and ¹³C data were reported together with high resolution mass spectrometric data or elemental analysis.

General procedure for the α -C-H bond amination of various alkyl ethers (8a-8h)

To a suspension of sodium hydride (60% dispersion in mineral oil, 20 mg, 0.5 mmol) in 3 mL of dry alkyl ether an amide or sulfonamide (0.5 mmol) was added at room temperature under nitrogen. After stirring for 3 hours at room temperature Ph_2IPF_6 (319 mg, 0.75 mmol) was added and the reaction mixture was left stirred for 6 hours. The solvent was removed under reduced pressure and resulting solid was subjected to the column chromatography (silica gel) to afford the product. For the new compounds, their ^1H and ^{13}C data were reported together with high resolution mass spectrometric data or elemental analysis.

General procedure for the synthesis of nucleoside analogues (10a-10d)

To a suspension of sodium hydride (60% dispersion in mineral oil, 20 mg, 0.5 mmol) in 1 mL of dry alkyl ether and N3-protected nucleobase (0.5 mmol) was added at room temperature under nitrogen. After stirring for 3 hours at room temperature Ph_2IPF_6 (362 mg, 0.85 mmol) in 2 mL of ether was added and the reaction mixture was left stirred for 6 hours. The solvent was removed under reduced pressure and resulting solid was subjected to the column chromatography (silica gel) to afford the product. For the new compounds, their ^1H and ^{13}C data were reported together with high resolution mass spectrometric data or elemental analysis.

6. Mechanistic studies

Reaction in the presence of TEMPO

Sodium hydride (60% dispersion in mineral oil, 20 mg, 0.5 mmol) was added to a stirred solution of N-benzylmethanesulfonamide (93 mg, 0.5 mmol) in 1 mL of dry tetrahydrofuran at room temperature under nitrogen. After stirring for 1 hour TEMPO (7.8 mg, 0.05 mmol) and Ph_2IPF_6 (256 mg, 0.6 mmol) was added, and the reaction mixture was left stirred for 6 hours. After the indicated time the reaction mixture was analyzed by GCMS using 30 μL of dodecane as an internal standard. **3a** was not detected.

Comparison of rate constants of the reactions of acetanilide (4d) with THF and THF- d_8

Four stock solutions were prepared: 405 mg of acetanilide and 102 mg of dodecane in 6.0 mL of THF (Solution A); 1.50 g of Ph_2IPF_6 in 5.0 mL of THF (Solution B); 405 mg of acetanilide and 102 mg of dodecane in 6.0 mL of THF- d_8 (Solution C); 1.50 g of Ph_2IPF_6 in 5.0 mL of THF- d_8 (Solution D). To 1.0 mL of Solution A 20 mg of sodium hydride (60% dispersion in mineral oil) was added and the mixture was stirred for 30 minutes. Then 1.0 mL of Solution B was added at once at room temperature (23,5 °C). The aliquotes of the reaction mixture were quenched with ethanol and analyzed by GC (calibration was performed using dodecane as an internal standard). The procedure was repeated with Solutions C and D. The ratio between both reaction rate constants was determined to be 4.60.




Figure S1. The rate of the reaction of acetanilide (**4d**) in THF





Figure S2. The rate of the reaction of acetanilide (**4d**) in THF- d_8

7. Detailed descriptions of the products




N-benzyl-N-(tetrahydrofuran-2-yl)methanesulfonamide (3a)

Isolated by gradient elution from the column with hexane-EtOAc (9:1 to 4:1) in 73% yield as a colorless oil.

¹H NMR (400 MHz, CDCl₃): 7.42 (d, *J* = 7.5 Hz, 2H), 7.37-7.34 (m, 2H), 7.30-7.26 (m, 1H), 5.72-5.69 (m, 1H), 4.57 (d, *J* = 16.7 Hz, 1H), 4.27 (d, *J* = 16.7 Hz, 1H), 4.07-4.01 (m, 1H), 3.84-3.79 (m, 1H), 2.97 (s, 3H), 2.08-1.81 (m, 3H), 1.75-1.69 (m, 1H).

¹³C NMR (101 MHz, CDCl₃): 138.3, 128.7, 127.5, 127.1, 88.8, 68.4, 46.6, 39.6, 29.6, 24.8.

HRESI-MS: calculated for (C₁₂H₁₇NO₃S, M+H), 256.1007; found, 256.1000.




N-cyclohexyl-N-(tetrahydrofuran-2-yl)methanesulfonamide (3b)

Isolated by gradient elution from the column with hexane-EtOAc (20:1 to 9:1) 76% yield as a colorless oil.

¹H NMR (400 MHz, CDCl₃): 5.34 (m, 1H), 4.05-3.99 (m, 1H), 3.77-3.73 (m, 1H), 3.38-3.31 (m, 1H), 2.98 (s, 3H), 2.19-2.02 (m, 3H), 1.92-1.60 (m, 8H), 1.34-1.08 (m, 3H).

¹³C NMR (101 MHz, CDCl₃): 88.7, 68.1, 57.5, 43.4, 34.2, 31.4, 31.0, 26.6, 25.3.

HRESI-MS: calculated for (C₁₁H₂₁NO₃S, M+Na), 270.1140; found, 270.1143.



N-(tert-butyl)-N-(tetrahydrofuran-2-yl)methanesulfonamide (3c)


Isolated by gradient elution from the column with hexane-EtOAc (19:1 to 9:1) in 39% yield as a white solid.

¹H NMR (400 MHz, CD₂Cl₂): 5.33-5.29 (m, 1H), 4.08-4.03 (m, 1H), 3.74-3.69 (m, 1H), 2.99 (s, 3H), 2.51-2.44 (m, 1H), 2.12-1.99 (m, 2H), 1.88-1.79 (m, 1H), 1.43 (s, 9H).

¹³C NMR (101 MHz, CD₂Cl₂): 90.6, 68.5, 59.7, 45.7, 32.9, 30.8, 25.8.

HRESI-MS: calculated for (C₉H₁₉NO₃S, M+Na), 244.0983; found, 244.0984.

Elemental analysis: Anal. Calcd for C₉H₁₉NO₃S: C, 48.84; H, 8.65; N 6.33. Found: C, 48.88; H, 8.35; N 6.15.




N-(2,2-dimethylpent-4-en-1-yl)-N-(tetrahydrofuran-2-yl)methanesulfonamide (3d)

Isolated by gradient elution from the column with hexane-EtOAc (6:1 to 4:1) in 78 % yield as colorless oil.

¹H NMR (400 MHz, CDCl₃): 5.88-5.78 (m, 1H), 5.32-5.03 (m, 3H), 4.11-4.06 (m, 1H), 3.81-3.76 (m, 1H), 3.24 (d, *J* = 14.7 Hz, 1H), 2.98 (s, 3H), 2.91 (d, *J* = 14.7 Hz, 1H), 2.54-2.45 (m, 1H), 2.22-2.10 (m, 2H), 2.03 (m, 2H), 1.89-1.82 (m, 1H), 0.95 (s, 3H), 0.94 (s, 3H).

¹³C NMR (101 MHz, CDCl₃): 134.8, 117.8, 94.7, 77.2, 68.6, 59.6, 45.4, 40.8, 35.5, 31.7, 25.737, 25.3, 25.1.

HRESI-MS: calculated for (C₁₂H₂₃NO₃S, M+H), 262.1477; found 262.1472.




N-allyl-N-(tetrahydrofuran-2-yl)methanesulfonamide (3e)

Eluted from the column with hexane-EtOAc (9:1) in 77% yield as a colorless oil

¹H NMR (400 MHz, CDCl₃): 5.97-5.87 (m, 1H), 5.63-5.60 (m, 1H), 5.28 (dd, *J* = 17.2, 1.4 Hz, 1H), 5.16 (dd, *J* = 10.2, 1.4 Hz, 1H), 3.99-3.93 (m, 1H), 3.82-3.78 (m, 3H), 2.93 (s, 3H), 2.13-2.05 (m, 1H), 1.98-1.85 (m, 3H).

¹³C NMR (101 MHz, CDCl₃): 135.5, 117.1, 88.7, 68.2, 45.4, 39.7, 29.4, 25.0.

HRESI-MS: calculated for (C₈H₁₅NO₃S, M+Na), 228.0670; found, 228.0668.



N-(1-phenylethyl)-N-(tetrahydrofuran-2-yl)methanesulfonamide

Isolated by gradient elution from the column with hexane-EtOAc (20:1 to 9:1) in 75 % yield as white solid. Diastereomeric ratio is 2:3 (**3f**:**3g**).

N-(1-phenylethyl)-N-(tetrahydrofuran-2-yl)methanesulfonamide (d.r- 2:3) major product (3f)

¹H NMR (400 MHz, CD₂Cl₂): 7.55 (d, *J* = 7.6 Hz, 2H), 7.38-7.27 (m, 3H), 5.48 (m, 1H), 4.89 (q, *J* = 7.24 Hz, 1H), 4.11-4.06 (m, 1H), 3.80-3.75 (m, 1H), 2.45 (s, 3H), 2.12-2.02 (m, 3H), 1.96-1.88 (m, 1H), 1.73 (d, *J* = 7.2 Hz, 3H).

¹³C NMR (101 MHz, CD₂Cl₂): 140.1, 129.00, 128.5, 128.00, 89.3, 67.9, 54.6, 42.4, 30.8, 25.5, 21.1.

HRESI-MS: calculated for (C₁₃H₁₉NO₃S, M+Na), 292.0983; found, 292.0981.


N-(1-phenylethyl)-N-(tetrahydrofuran-2-yl)methanesulfonamide (d.r- 2:3) minor product (3g)

Contains 15% of major isomer.

¹H NMR (400 MHz, CD₂Cl₂): 7.41-7.24 (m, 5H), 5.06-5.02 (m, 2H), 4.03-3.98 (m, 1H), 3.71-3.66 (m, 1H), 3.04 (s, 3H), 2.28-2.22 (m, 1H), 2.02-1.97 (m, 1H), 1.77-1.72 (m, 5H).

¹³C NMR (101 MHz, CD₂Cl₂): 142.2, 128.7, 127.5, 127.4, 89.3, 68.5, 55.6, 53.8, 43.8, 31.34, 25.5, 17.9.

Elemental analysis: Anal. Calcd for C₁₃H₁₉NO₃S: C, 57.97; H, 7.11; N 5.20. Found: C, 57.64; H, 7.20; N 4.88.




N-phenyl-N-(tetrahydrofuran-2-yl)methanesulfonamide (3h)

Eluted from the column with CH₂Cl₂ in 59 % yield as a white solid.

¹H NMR (400 MHz, CDCl₃): 7.46-7.44 (m, 2H), 7.42-7.27 (m, 3H), 6.03-6.00 (dd, *J* = 7.1, 6.0 Hz, 1H), 3.92-3.87 (m, 1H), 3.78-3.72 (m, 1H), 3.07 (s, 3H), 2.13-2.04 (m, 1H), 1.77-1.59 (m, 2H), 1.46-1.36 (m, 1H).

¹³C NMR (101 MHz, CDCl₃): 136.2, 131.4, 129.3, 129.1, 89.5, 68.4, 39.8, 29.7, 24.8.

HRESI-MS: calculated for (C₁₁H₁₅NO₃S, M+H), 242.0851; found, 242.0853.




N-hexyl-4-methyl-N-(tetrahydrofuran-2-yl)benzenesulfonamide (3i)

Eluted from the column with hexane-EtOAc (9:1) in 67% yield as a colorless oil.

¹H NMR (400 MHz, CDCl₃): 7.78 (d, *J* = 8.3 Hz, 2H), 7.28 (d, *J* = 8.1, 2H), 5.80-5.76 (m, 1H), 3.91-3.85 (m, 1H), 3.76-3.71 (m, 1H), 3.02-2.88 (m, 2H), 2.41 (s, 3H), 2.17-2.11 (m, 1H), 1.95-1.76 (m, 4H), 1.61-1.50 (m, 1H), 1.32-1.19 (m, 6H), 0.88 (t, *J* = 6.7 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃): 143.2, 137.2, 129.5, 127.8, 88.8, 68.1, 43.4, 31.5, 31.5, 30.3, 26.9, 25.0, 22.7, 21.6, 14.1.

HRESI-MS: calculated for (C₁₇H₂₇NO₃S, M+Na), 348.1609; found, 348.1610.




N-cyclohexyl-4-methyl-N-(tetrahydrofuran-2-yl)benzenesulfonamide (3j)

Eluted from the column with hexane-EtOAc (9:1) in 43% yield as a colorless oil.

¹H NMR (400 MHz, CDCl₃): 7.81 (d, *J* = 8.3 Hz, 2H), 7.25 (d, *J* = 8.6 Hz, 2H), 5.44-5.30 (m, 1H), 4.11-4.06 (m, 1H), 3.80-3.76 (m, 1H), 3.30-3.26 (m, 1H), 2.40 (s, 3H), 2.35-2.29 (m, 1H), 2.15-2.07 (m, 2H), 1.95-1.43 (m, 8H), 1.26-0.99 (m, 3H).

¹³C NMR (101 MHz, CDCl₃): 142.8, 140.0, 129.4, 127.4, 88.8, 68.1, 57.7, 33.8, 31.4, 26.7, 25.5, 25.4, 21.6.

HRESI-MS: calculated for (C₁₇H₂₅NO₃S, M+H), 324.1633; found, 324.1639.




N-isopropyl-4-methyl-N-(tetrahydrofuran-2-yl)benzenesulfonamide (3k)

Isolated by gradient elution from the column with hexane-EtOAc (9:1 to 4:1) in 63 % yield as a colorless oil.

¹H NMR (400 MHz, CDCl₃): 7.72 (d, *J* = 8.3 Hz, 2H), 7.17 (d, *J* = 8.1 Hz, 2H), 5.30 (t, *J* = 7.0 Hz, 1H), 4.02-3.96 (m, 1H), 3.72-3.63 (m, 2H), 2.31 (s, 3H), 2.28-2.22 (m, 1H), 2.08-2.01 (m, 2H), 1.85-1.77 (m, 1H), 1.19 (d, *J* = 6.8 Hz, 3H), 1.00 (d, *J* = 6.8 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃): 142.8, 139.7, 129.4, 127.5, 88.3, 68.0, 49.1, 31.3, 25.4, 23.4, 21.6, 21.0.

HRESI-MS: calculated for (C₁₄H₂₁NO₃S, M+H), 284.1320; found 284.1316.




N-allyl-4-methyl-N-(tetrahydrofuran-2-yl)benzenesulfonamide (3l)

Eluted from the column with hexane-EtOAc (3:1) in 73 % yield as a colorless oil.

¹H NMR (400 MHz, CDCl₃): 7.78 (d, *J* = 8.2 Hz, 2H), 7.28 (d, *J* = 8.2 Hz, 2H), 5.93-5.84 (m, 2H), 5.23 (dd, *J* = 17.2, 1.2 Hz, 1H), 5.10 (dd, *J* = 10.0, 1.2 Hz, 1H), 3.90-3.84 (m, 1H), 3.76-3.67 (m, 3H), 2.42 (s, 3H), 2.16-2.08 (m, 1H), 2.00-1.85 (m, 3H).

¹³C NMR (101 MHz, CDCl₃): 143.3, 137.1, 136.0, 129.5, 127.8, 116.4, 88.8, 68.3, 45.2, 30.0, 25.0, 21.6.

HRESI-MS: calculated for (C₁₄H₁₉NO₃S, M+H), 282.1164; found, 282.1166.




N-(2,2-dimethylpent-4-en-1-yl)-4-methyl-N-(tetrahydrofuran-2-yl)benzenesulfonamide (3m)

Isolated by gradient elution from the column with hexane-EtOAc (9:1 to 6:1) in 62% yield as a colorless oil.

¹H NMR (400 MHz, CDCl₃): 7.77 (d, *J* = 8.2 Hz, 2H), 7.28 (d, *J* = 8.2 Hz, 2H), 5.89-5.78 (m, 1H), 5.27-5.24 (m, 1H), 5.08-5.02 (m, 2H), 4.00-3.95 (m, 1H), 3.71-3.67 (m, 1H), 3.27 (d, *J* = 15.2 Hz, 1H), 2.83 (d, *J* = 15.2 Hz, 1H), 2.42 (s, 3H), 2.36-2.27 (m, 1H), 2.14-2.06 (m, 1H), 1.90-1.81 (m, 1H), 0.99 (s, 6H).

¹³C NMR (101 MHz, CDCl₃): 143.1, 138.4, 135.1, 129.3, 127.90, 117.7, 93.1, 68.0, 57.7, 45.9, 35.2, 31.3, 26.2, 25.8, 25.0, 21.6.

HRESI-MS: calculated for (C₁₈H₂₇NO₃S, M+Na), 360.1609; found, 360.1611




N-benzyl-4-methyl-N-(tetrahydrofuran-2-yl)benzenesulfonamide (3n)

Isolated by gradient elution from the column with hexane-EtOAc (9:1 to 4:1) in 61% yield as a white solid.

¹H NMR (400 MHz, CDCl₃): 7.81 (d, *J* = 8.2 Hz, 2H), 7.43 (d, *J* = 7.5 Hz, 2H), 7.35-7.27 (m, 5 H), 5.95-5.92 (m, 1H), 4.44 (d, *J* = 17.0 Hz, 1H), 4.15 (d, *J* = 17.0 Hz, 1H), 3.91-3.86 (m, 1H), 3.78-3.73 (m, 1H), 2.44 (s, 3H), 2.03-1.97 (m, 1H), 1.95-1.64 (m, 3H).

¹³C NMR (101 MHz, CDCl₃): 143.4, 138.5, 136.9, 129.5, 128.5, 127.8, 127.2, 127.1, 88.9, 68.5, 46.0, 30.2, 24.8, 21.6.

HRESI-MS: calculated for (C₁₈H₂₁NO₃S, M+H), 332.1320; found, 332.1311




N-(2,2-dimethylpent-4-en-1-yl)-N-(tetrahydrofuran-2-yl)acetamide (5a)

Eluted from the column with hexane-EtOAc (5:1) in 54 % yield as a pale yellow oil.

¹H NMR (400 MHz, CD₂Cl₂): 5.91-5.80 (m, 1H), 5.35 (br, 1H), 5.03-4.99 (m, 2H), 3.98 (m, 1H), 3.74-3.69 (m, 1H), 3.38 (d, *J* = 13.5 Hz, 1H), 3.04 (d, *J* = 13.5 Hz, 1H), 2.13-1.92 (m, 9H), 0.87 (s, 6H)

¹³C NMR (101 MHz, CD₂Cl₂): 172.5, 136.1, 117.1, 90.7, 67.3, 52.7, 46.3, 36.0, 30.1, 26.0, 25.8, 25.4, 23.2.

HRESI-MS: calculated for (C₁₃H₂₃NO₂, M+H), 226.1807; found 226.1811.




N-allyl-N-(tetrahydrofuran-2-yl)acetamide (5b)

Isolated by gradient elution from the column with hexane-EtOAc (9:1 to 6:1) in 82% as a colorless oil.

¹H NMR (400 MHz, DMSO-d₆, 373K): 5.87-5.73 (m, 2H), 5.12 (dd, *J* = 17.4, 1.4 Hz, 1H), 5.07 (dd, *J* = 10.4, 1.4 Hz, 1H), 3.93-3.84 (m, 3H), 3.71-3.67 (m, 1H), 2.07-2.02 (m, 4H), 1.98-1.82 (m, 3H).

¹³C NMR (101 MHz, DMSO-d₆, 373K): 170.2, 135.5, 114.3, 86.1, 66.4, 43.3, 28.3, 24.1, 21.0.

HRESI-MS: calculated for (C₉H₁₅NO₂, M+Na), 192.1001; found 192.1008.




N-benzyl-N-(tetrahydrofuran-2-yl)acetamide (5c)

Eluted from the column with hexane-EtOAc (4:1) in 71 % yield as an off-white solid.

¹H NMR (400 MHz, DMSO-d₆, 373K): 7.30-7.21 (m, 5H), 5.84 (m, 1H), 4.58 (d, *J* = 16.7 Hz, 1H), 4.40 (d, *J* = 16.7 Hz, 1H), 3.90-3.85 (m, 1H), 3.72-3.67 (m, 1H), 2.08-2.01 (m, 4H), 1.91-1.73 (m, 3H).

¹³C NMR (101 MHz, DMSO-d₆, 373K): 170.1, 138.9, 127.4, 126.7, 125.8, 86.6, 66.4, 44.4, 28.5, 24.1, 21.2.

HRESI-MS: calculated for (C₁₃H₁₇NO₂, M+H), 220.1338; found 220.1341.




N-phenyl-N-(tetrahydrofuran-2-yl)acetamide (5d)

Isolated by gradient elution from the column with hexane-EtOAc (4:1 to 2:1) in 95 % yield as a white solid

¹H NMR (400 MHz, CD₂Cl₂): 7.43-7.20 (m, 5H), 6.45 (br, 1H), 3.63-3.60 (m, 2H), 2.03-1.98 (m, 1H), 1.72-1.62 (m, 5H), 1.25-1.22 (m, 1H).

¹³C NMR (101 MHz, CD₂Cl₂): 171.1, 139.5, 131.0, 129.5, 128.6, 84.4, 68.4, 29.5, 25.3, 23.6.

HRESI-MS: calculated for (C₁₂H₁₅NO₂, M+H), 206.1181; found 206.1177.




2,2,2-trifluoro-N-hexyl-N-(tetrahydrofuran-2-yl)acetamide (5e)

Isolated by gradient elution from the column with hexane-EtOAc (20:1 to 10:1) in 62% yield as a colorless oil.

¹H NMR (400 MHz, DMSO-d₆, 373K): 5.63-5.60 (m, 1H), 4.05-3.99 (m, 1H), 3.82-3.77 (m, 1H), 3.41-3.34 (m, 1H), 3.26-3.19 (m, 1H), 2.25-2.20 (m, 1H), 2.03-1.92 (m, 3H), 1.68-1.52 (m, 2H), 1.35-1.29 (m, 6H), 0.89 (t, *J* = 6.5 Hz, 3H).

¹³C NMR (101 MHz, DMSO-d₆, 373K): 155.1 (q, *J* = 35 Hz), 115.7 (q, *J* = 289 Hz), 87.0, 67.7, 42.3, 30.0, 29.2, 27.5, 25.4, 24.0, 21.1, 12.7.

HRESI-MS: calculated for (C₁₂H₂₀F₃NO₂, M+Na), 290.1344; found, 290.1348.




N-(tert-butyl)-2,2,2-trifluoro-N-(tetrahydrofuran-2-yl)acetamide (5f)

Eluted from the column with hexane-EtOAc (5:1) in 58% yield as a colorless oil.

¹H NMR (400 MHz, CD₂Cl₂): 5.40 (m, 1H), 4.06-4.01 (m, 1H), 3.71-3.65 (m, 1H), 2.20-2.08 (m, 3H), 1.99-1.93 (m, 1H), 1.49 (s, 9H)

¹³C NMR (101 MHz, CD₂Cl₂): 159.1 (q, *J* = 37 Hz), 117.0 (q, *J* = 290 Hz), 88.9, 67.0, 60.2, 31.1, 28.8, 24.7.

HRESI-MS: calculated for (C₁₀H₁₆F₃NO₂, M+Na), 262.1031; found, 262.1035.




N-allyl-2,2,2-trifluoro-N-(tetrahydrofuran-2-yl)acetamide (5g)

Eluted from the column with hexane-EtOAc (9:1) in 80 % yield as a yellowish oil.

¹H NMR (400 MHz, DMSO-d₆, 373K): 5.90-5.81 (m, 1H), 5.70-5.67 (m, 1H), 5.22-5.13 (m, 2H), 4.05-3.99 (m, 3H), 3.82-3.77 (m, 1H), 2.26-2.18 (m, 1H), 2.08-1.90 (m, 3H)

¹³C NMR (101 MHz, DMSO-d₆, 373K): 155.3 (q, *J* = 35 Hz), 133.3, 115.7, 115.6 (q, *J* = 290 Hz), 86.8, 67.7, 43.9, 29.0, 23.9.

HRESI-MS: calculated for (C₉H₁₂F₃NO₂, M+Na), 246.0718; found, 246.0720.




N-benzyl-2,2,2-trifluoro-N-(tetrahydrofuran-2-yl)acetamide (5h)

Isolated by gradient elution from the column with hexane-EtOAc (3:1 to 2:1) in 89 % yield as slightly yellowish oil.

¹H NMR (400 MHz, CD₂Cl₂): 7.25-7.15 (m, 5H), 5.70 (m, 1H), 4.54 (d, *J* = 15.7 Hz, 1H), 4.38 (d, *J* = 15.8 Hz, 1H), 3.97-3.91 (m, 1H), 3.77-3.72 (m, 1H), 2.11-2.03 (m, 1H), 1.91-1.72 (m, 3H).

¹³C NMR (101 MHz, CD₂Cl₂): 157.2 (q, *J* = 36 Hz), 137.5, 128.9, 127.6, 127.1, 117.0 (q, *J* = 289 Hz), 87.9, 69.2, 45.9, 30.5, 25.7.

HRESI-MS: calculated for (C₁₃H₁₄F₃NO₂, M+Na), 296.0874; found, 296.0873.




Ethyl-4-(N-(tetrahydrofuran-2-yl)acetamido)benzoate (5i)

Eluted from the column with hexane-EtOAc (3:1) in 93 % yield as a colorless oil.

¹H NMR (400 MHz, CD₂Cl₂): 8.07 (d, *J* = 8.5 Hz, 2H), 7.38-7.27 (br, 2H), 6.48-6.36 (br, 1H), 4.37 (q, *J* = 7.1 Hz, 2H), 3.65-3.61 (m, 2H), 2.08-2.00 (m, 1H), 1.78-1.58 (br+m, 5H), 1.38 (t, *J* = 7.1 Hz, 3H), 1.30-1.23 (m, 1H).

¹³C NMR (101 MHz, CD₂Cl₂) δ 170.7, 166.1, 143.7, 131.0, 130.7, 118.8, 85.1, 68.5, 61.6, 29.7, 25.3, 23.63, 14.5.

HRESI-MS: calculated for (C₁₅H₁₉NO₄, M+Na), 300.1212; found 300.1206.




N-(4-cyanophenyl)-N-(tetrahydrofuran-2-yl)acetamide (5j)

Isolated by gradient elution from the column with hexane-EtOAc (4:1 to 3:2) in 89 % yield as a colorless oil.

¹H NMR (400 MHz, CD₃CN): 7.79 (d, *J* = 7.4 Hz, 2H), 7.43 (d, *J* = 7.6 Hz, 2H), 6.27 (br, 1H), 3.61 (m, 2H), 2.08-1.99 (m, 1H), 1.76-1.54 (m, 5H), 1.27-1.18 (m, 1H).

¹³C NMR (101 MHz, CD₃CN): 171.5, 144.26, 134.1, 132.5, 119.1, 112.7, 85.9, 68.7, 29.9, 25.4, 23.5.

HRESI-MS: calculated for (C₁₃H₁₄N₂O₂, M+Na), 253.0953; found 253.0956.




N-(tetrahydrofuran-2-yl)-N-(4-(trifluoromethyl)phenyl)acetamide (5k)

Eluted from the column with hexane-EtOAc (7:3) in 95 % yield as a colorless oil.

¹H NMR (400 MHz, CD₂Cl₂): 7.69 (d, *J* = 8.1 Hz, 2H), 7.48-7.35 (br, 2H), 6.51-6.32 (br, 1H), 3.68-3.63 (m, 2H), 2.10-2.00 (m, 1H), 1.87-1.55 (m, 5H), 1.33-1.23 (m, 1H).

¹³C NMR (101 MHz, CD₂Cl₂): 170.7, 143.0, 131.6, 130.6 (q, *J* = 32 Hz), 126.7, 124.4 (q, *J* = 273 Hz), 84.9, 68.4, 29.6, 25.3, 23.6.

HRESI-MS: calculated for (C₁₃H₁₄F₃NO₂, M+Na), 296.0874; found 296.0865.




N-(4-bromophenyl)-N-(tetrahydrofuran-2-yl)acetamide (5l)

Isolated by gradient elution from the column with hexane-EtOAc (4:1 to 2:1) in 95 % yield as a white solid

¹H NMR (400 MHz, CD₂Cl₂): 7.55 (d, *J* = 8.2 Hz, 2H), 7.30-6.99 (br, 2H), 6.42 (br, 1H), 3.66-3.60 (m, 2H), 2.07-1.98 (m, 1H), 1.82-1.57 (m, 5H), 1.34-1.24 (m, 1H).

¹³C NMR (101 MHz, CD₂Cl₂): 170.8, 138.6, 132.7, 122.6, 84.4, 68.4, 29.6, 25.3, 23.7.

HRESI-MS: calculated for (C₁₂H₁₄BrNO₂, M+Na), 306.0106; found 306.0117.




N-(4-iodophenyl)-N-(tetrahydrofuran-2-yl)acetamide (5m)

Isolated by gradient elution from the column with hexane-EtOAc (4:1 to 2:1) in 90 % yield as a white solid

¹H NMR (400 MHz, CD₃CN): 7.78 (d, *J* = 8.2 Hz, 2H), 7.07-7.03 (br, 2H), 6.42-6.32 (br, 1H), 3.60-3.54 (m, 2H), 2.03-1.94 (m, 1H), 1.77-1.56 (m, 1H), 1.26-1.20 (m, 1H).

¹³C NMR (101 MHz, CD₃CN): 171.0, 140.0, 139.3, 133.8, 94.3, 84.8, 68.7, 29.9, 25.5, 23.6.

HRESI-MS: calculated for (C₁₂H₁₄INO₂, M+H), 332.0148; found 332.0164.




N-(4-methoxyphenyl)-N-(tetrahydrofuran-2-yl)acetamide (5n)

Eluted from the column with hexane-EtOAc (4:1) in 93 % yield as a beige solid.

¹H NMR (400 MHz, CD₂Cl₂): 7.26 (br, 1H), 7.05 (br, 1H), 6.91 (d, *J* = 8.24 Hz, 2H), 6.38 (m, 1H), 3.82 (s, 3H), 3.67-3.63 (m, 2H), 2.05-1.95 (m, 1H), 1.76-1.63 (m, 5H), 1.31-1.24 (m, 1H)

¹³C NMR (101 MHz, CD₂Cl₂): 172.5, 159.8, 131.9, 122.0, 114.6, 84.6, 68.5, 55.8, 29.4, 25.3, 23.6.

HRESI-MS: calculated for (C₁₃H₁₇NO₃, M+H), 236.1287; found 236.1278.




N-(6-methylpyridin-2-yl)-N-(tetrahydrofuran-2-yl)acetamide (5o)

Isolated by gradient elution from the column with hexane-EtOAc (10:1 to 2:1) in 86 % yield as a colorless oil.

¹H NMR (400 MHz, CD₂Cl₂): 7.69 (t, *J* = 7.7 Hz, 1H), 7.20 (d, *J* = 7.6 Hz, 1H), 7.11 (d, *J* = 7.7 Hz, 1H), 6.31-6.28 (m, 1H), 3.74-3.65 (m, 2H), 2.53 (s, 3H), 2.08-2.00 (m, 1H), 1.80-1.66 (m, 5H), 1.37-1.25 (m, 1H).

¹³C NMR (101 MHz, CD₂Cl₂): 171.9, 159.4, 152.3, 139.0, 123.4, 122.1, 85.7, 68.6, 29.3, 25.1, 24.3, 23.5.

HRESI-MS: calculated for (C₁₂H₁₆N₂O₂, M+H), 221.1290; found 221.1292.




2-(tetrahydrofuran-2-yl)isoindoline-1,3-dione (5p)

Isolated by gradient elution from the column with hexane-EtOAc (9:1 to 6:1) in 75% yield as a white solid.

¹H NMR (400 MHz, CDCl₃): 7.86 (m, 2H), 7.73 (m, 2H), 6.06-6.03 (m, 1H), 4.23-4.16 (m, 1H), 3.96-3.93 (m, 1H), 2.57-2.50 (m, 1H), 2.42-2.24 (m, 2H), 2.04-1.98 (m, 1H).


¹³C NMR (101 MHz, CDCl₃): 168.0, 134.3, 132.0, 123.5, 81.0, 67.0, 29.3, 26.2.

HRESI-MS: calculated for (C₁₂H₁₁NO₄, M+H), 218.0817; found, 218.0812




1-(Tetrahydrofuran-2-yl)-1H-imidazole (7a)

Isolated by flash column chromatography (methanol/ dichloromethane = 1:10) in 52% as colorless oil. ¹H and ¹³C NMR spectra of the compound correspond to that published before.⁶



1-(Tetrahydrofuran-2-yl)-1H-benzo[d]imidazole (7b)

Isolated by flash column chromatography (methanol/ dichloromethane = 1:10) in 85% yield as colorless oil. ¹H and ¹³C NMR spectra of the product correspond to that published before.⁶




N-[Tetrahydrofuran-2-yl]-1H-indole (7c)

Isolated by gradient elution from the column with hexane-EtOAc (20:1 to 9:1) in 57% yield as a colorless liquid.

¹H NMR (400 MHz, CD₂Cl₂): 7.59 (d, *J* = 7.7 Hz, 1H), 7.46 (d, *J* = 8.2 Hz, 1H), 7.25 – 7.18 (m, 2H), 7.12 (dd, *J* = 7.6, 7.6 Hz, 1H), 6.51 (d, *J* = 3.0 Hz, 1H), 6.22 (dd, *J* = 5.7, 4.2 Hz, 1H), 4.13-4.07 (m, 1H), 4.00-3.94 (m, 1H), 2.47-2.37 (m, 2H), 2.23-2.08 (m, 2H).

¹³C NMR (101 MHz, CD₂Cl₂): 136.1, 129.5, 124.5, 122.0, 121.1, 120.2, 110.4, 102.4, 86.2, 68.7, 31.9, 25.2.

GCMS: [M] = 187 detected which corresponds to C₁₂H₁₃NO; the purity was further confirmed by GCMS.




9-(tetrahydrofuran-2-yl)-9H-carbazole (7d)

Isolated by gradient elution from the column with hexane-EtOAc (15:1 to 9:1) in 65% yield as a white solid

¹H NMR (400 MHz, CDCl₃): 8.10 (d, *J* = 8.48 Hz, 2H), 7.54-7.39 (m, 4H), 7.29-7.24 (m, 2H), 6.52-6.49 (m, 1H), 4.44-4.39 (m, 1H), 4.10-4.06 (m, 1H), 2.56-2.47 (m, 1H), 2.42-2.20 (m, 3H).

¹³C NMR (101 MHz, CDCl₃): 139.1, 125.8, 123.9, 120.4, 119.7, 110.5, 86.6, 68.2, 29.5, 25.8.

HRESI-MS: calculated for (C₁₆H₁₅NO, M+H), 238.1232; found, 238.1241




N-benzyl-N-(1,4-dioxan-2-yl)methanesulfonamide (8a)

Isolated by gradient elution from the column with hexane-EtOAc (6:1 to 4:1) in 47 % yield as a beige solid.

¹H NMR (400 MHz, CD₂Cl₂): 7.39-7.24 (m, 5H), 5.20-5.17 (m, 1H), 4.54 (d, *J* = 16.6 Hz, 1H), 4.43 (d, *J* = 16.6 Hz, 1H), 3.87-3.83 (m, 2H), 3.61-3.58 (m, 1H), 3.48-3.40 (m, 2H), 3.26-3.21 (m, 1H), 2.97 (s, 3H).

¹³C NMR (101 MHz, CD₂Cl₂): 138.6, 128.9, 127.8, 127.6, 83.4, 69.3, 67.3, 66.0, 47.8, 40.3.

HRESI-MS: calculated for (C₁₂H₁₇NO₄S, M+Na), 294.0776; found 294.0779.




2-(1,4-dioxan-2-yl)isoindoline-1,3-dione (8b)

Isolated by gradient elution from the column with hexane-EtOAc (9:1 to 4:1) in 85% yield as a white solid.

¹H NMR (400 MHz, CDCl₃): 7.87 (m, 2H), 7.76 (m, 2H), 5.56-5.53 (m, 1H), 4.61-4.56 (m, 1H), 3.98-3.95 (m, 2H), 3.78-3.76 (m, 3H).

¹³C NMR (101 MHz, CDCl₃): 167.2, 134.6, 131.7, 123.8, 76.3, 67.7, 66.5, 65.8.

HRESI-MS: calculated for (C₁₂H₁₁NO₄, M+H), 234.0766; found, 234.0768.




N-benzyl-N-(tetrahydro-2H-pyran-2-yl)methanesulfonamide (8c)

Isolated by gradient elution from the column with hexane-EtOAc (9:1 to 6:1) in 68 % yield as a white solid.

^1H NMR (400 MHz, CD_2Cl_2): 7.39-7.24 (m, 5H), 5.03-5.01 (m, 1H), 4.53-4.40 (m, 2H), 4.01-3.98 (m, 1H), 3.59-3.53 (m, 1H), 2.93 (s, 3H), 1.79-1.76 (m, 1H), 1.56-1.36 (m, 5H)

^{13}C NMR (101 MHz, CD_2Cl_2): 139.4, 128.7, 127.4, 127.4, 86.8, 68.4, 47.1, 40.0, 31.4, 25.4, 23.9.

HRESI-MS: calculated for ($\text{C}_{13}\text{H}_{19}\text{NO}_3\text{S}$, $\text{M}+\text{Na}$), 292.0983; found 292.0977.




2-(tetrahydro-2H-pyran-2-yl)isoindoline-1,3-dione 31 (8d)

Isolated by gradient elution from the column with hexane-EtOAc (9:1 to 6:1) in 43 % yield as a white solid.

^1H NMR (400 MHz, CD_2Cl_2): 7.85 (m, 2 H), 7.74 (m, 2H), 5.30-5.26 (m, 1H), 4.06-4.03 (m, 1H), 3.65-3.59 (m, 1H), 2.76-2.66 (m, 1H), 2.02-1.98 (m, 1H), 1.71-1.52 (m, 4H).

^{13}C NMR (101 MHz, CD_2Cl_2): 167.7, 134.6, 132.2, 123.7, 79.6, 69.2, 28.2, 25.4, 24.0.

HRESI-MS: calculated for ($\text{C}_{13}\text{H}_{13}\text{NO}_3$, $\text{M}+\text{H}$), 232.0974; found 232.0963.




N-allyl-N-(5-methyltetrahydrofuran-2-yl)methanesulfonamide (8e)

Isolated by gradient elution from the column with hexane-EtOAc (20:1 to 10:1) in 61 % yield as a colorless oil. The ratio of two diastereomers is 2:3.

^1H NMR (400 MHz, CD_2Cl_2): 6.00-5.89 (m, $1\text{H}_{\text{overlap}}$), [5.68-5.65 (m, $0.6\text{H}_{\text{major}}$), 5.57-5.54 (m, $0.4\text{H}_{\text{minor}}$)], 5.30 (m, $1\text{H}_{\text{overlap}}$), 5.16 (m, $1\text{H}_{\text{overlap}}$), [4.26-4.20 (m, $0.6\text{H}_{\text{major}}$), 3.97-3.92 (m, $0.4\text{H}_{\text{minor}}$)], 3.85-3.73 (m, $2\text{H}_{\text{overlap}}$) 2.90 (s, $3\text{H}_{\text{overlap}}$), 2.16-1.92 (m, $3\text{H}_{\text{overlap}}$), 1.53-1.41 (m, $1\text{H}_{\text{overlap}}$), [1.26 (d, $J = 6.0$ Hz, $1.2\text{H}_{\text{minor}}$), 1.18 (d, $J = 6.0$ Hz, $1.8\text{H}_{\text{major}}$).]

^{13}C NMR (101 MHz, CD_2Cl_2): 136.3, 136.1, 116.8, 116.7, 88.8, 88.6, 76.7, 75.1, 45.8, 45.7, 39.9, 39.8, 33.2, 32.0, 30.9, 29.8, 21.7, 21.00

HRESI-MS: calculated for ($\text{C}_9\text{H}_{17}\text{NO}_3\text{S}$, $\text{M}+\text{Na}$), 242.0827; found 242.0818.




N-benzyl-N-(1,2-dimethoxyethyl)methanesulfonamide (8f)

Isolated by gradient elution from the column with hexane-EtOAc (9:1 to 4:1) in 50 % yield as a colorless oil

^1H NMR (400 MHz, CD_2Cl_2): 7.43-7.28 (m, 5H), 5.11-5.08 (m, 1H), 4.43 (d, $J = 15.8$ Hz, 1H), 4.29 (d, $J = 15.8$ Hz, 1H), 3.47 (m, 2H), 3.32 (s, 3H), 3.25 (s, 3H), 2.77 (s, 3H).

^{13}C NMR (101 MHz, CD_2Cl_2): 138.1, 129.0, 128.7, 127.8, 87.8, 71.8, 59.0, 55.9, 46.0, 41.9.

HRESI-MS: calculated for (C₁₂H₁₉NO₄S, M+Na), 296.0933; found 296.0942.




N-benzyl-N-(1,2-dimethoxyethyl)-2,2,2-trifluoroacetamide (8g)

Isolated by gradient elution from the column with hexane-EtOAc (10:1 to 5:1) in 41 % yield as a colorless oil.

¹H NMR (400 MHz, CD₂Cl₂): 7.32-7.26 (m, 5H), 5.16 (m, 1H), 4.68 (d, *J* = 15.3 Hz, 1H), 4.53 (d, *J* = 15.3 Hz, 1H), 3.47-3.40 (m, 1H), 3.34-3.28 (m, 4H), 3.17 (s, 3H).

¹³C NMR (101 MHz, CD₂Cl₂): 156.7 (q, *J* = 33 Hz), 137.3, 128.7, 128.2, 119.7 (q, *J* = 289 Hz), 87.3, 72.1, 59.1, 56.2, 44.7.

HRESI-MS: calculated for (C₁₃H₁₆F₃NO₃, M+Na), 314.0980; found 314.0975.




N-benzyl-2,2,2-trifluoro-N-((2-methoxyethoxy)methyl)acetamide (8g')

Isolated by gradient elution from the column with hexane-EtOAc (10:1 to 5:1) in 20 % yield as a colorless oil.

¹H NMR (400 MHz, CD₂Cl₂): 7.39-7.23 (m, 5H), 4.81 (d, *J* = 14.9 Hz, 2H), 4.70 (s, 2H), 3.62-3.50 (m, 2H), 3.48 (m, 2H), 3.33 (s, 3H).

¹³C NMR (101 MHz, CD₂Cl₂): 157.3 (q, *J* = 34 Hz), 135.9, 129.1, 128.8, 128.3, 116.8 (q, *J* = 287 Hz), 77.0, 72.0, 68.0, 59.1, 48.5.

HRESI-MS: calculated for (C₁₃H₁₆F₃NO₃, M+Na), 314.0980; found 314.0974.




N-allyl-N-(1,2-dimethoxyethyl)methanesulfonamide (8h)

Eluted from the column with hexane-EtOAc (7:3) in 56 % yield as a colorless oil

¹H NMR (400 MHz, CD₂Cl₂): 5.90-5.81 (m, 1H), 5.28 (dd, *J* = 17.2 Hz, 1.5 Hz, 1H), 5.17 (dd, *J* = 10.2 Hz, 1.3 Hz, 1H), 5.03 (m, 1H), 3.83 (d, *J* = 6.28 Hz, 2H), 3.49-3.39 (m, 2H), 3.34 (s, 3H), 3.30 (s, 3H), 2.91 (s, 3H).

¹³C NMR (101 MHz, CD₂Cl₂): 135.5, 118.1, 87.3, 71.8, 59.0, 55.5, 44.4, 42.5.

HRESI-MS: calculated for (C₈H₁₇NO₄S, M+Na), 246.0776; found 246.0780.




3-(4-methoxybenzyl)-5-methylpyrimidine-2,4(1H,3H)-dione (9a)

¹H NMR (400 MHz, CDCl₃): 9.59 (br, 1H), 7.43 (d, *J* = 8.3 Hz, 2H), 6.99 (d, *J* = 5.2 Hz, 1H), 6.83 (d, *J* = 8.3 Hz, 2H), 5.05 (s, 2H), 3.77 (s, 3H), 1.92 (s, 3H).

¹³C NMR (101 MHz, CDCl₃): 164.1, 159.2, 153.1, 134.3, 130.7, 129.1, 113.8, 110.5, 55.4, 43.5, 13.2.

HRESI-MS: calculated for (C₁₃H₁₄N₂O₃, M+H), 247.1083; found 247.1088.




3-(4-methoxybenzyl)-5-methyl-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (10a)

Isolated by gradient elution from the column with hexane-EtOAc (10:1 to 4:1) in 85 % yield as white solid.

¹H NMR (101 MHz, CD₂Cl₂): 7.36 (d, *J* = 8.5 Hz, 2H), 7.11 (s, 1H), 6.81 (d, *J* = 8.5 Hz, 2H), 6.01 (dd, *J* = 6.1, 2.9 Hz, 1H), 5.04-4.96 (m, 2H), 4.20-4.15 (m, 1H), 3.95-3.90 (m, 1H), 3.75 (s, 3H), 2.39-2.29 (m, 1H), 2.03-1.90 (m, 6H).

¹³C NMR (101 MHz, CD₂Cl₂): 163.8, 159.4, 151.2, 133.6, 130.6, 129.9, 113.8, 109.7, 87.7, 70.3, 55.6, 43.9, 33.0, 24.5, 13.5.

HRESI-MS: calculated for (C₁₇H₂₀N₂O₄, M+H), 317.1501; found 317.1509.




di-tert-butyl 5-fluoro-2,4-dioxypyrimidine-1,3(2H,4H)-dicarboxylate (9b')

Recrystallized from hexane-EtOAc (10:1) in 68 % yield

¹H NMR (400 MHz, CDCl₃): 7.97 (d, *J* = 6.44 Hz, 1H), 1.60 (s, 18H)

¹³C NMR (101 MHz, CDCl₃): 154.5 (d, *J* = 28.8 Hz), 147.5, 146.1, 144.2, 139.9 (d, *J* = 243.4 Hz), 123.4 (d, *J* = 37.0 Hz), 88.4, 88.2, 27.9, 27.5.

HRESI-MS: calculated for (C₁₄H₁₉FN₂O₆, M+Na), 353.1125; found 353.1130.




tert-butyl 5-fluoro-2,6-dioxo-3,6-dihydropyrimidine-1(2H)-carboxylate (9b)

Isolated by flash chromatography on silica gel (eluent - hexane-EtOAc 3:2) in 40% yield

¹H NMR (400 MHz, DMSO-d₆): 11.53 (s, 1H), 7.98 (d, *J* = 6.04 Hz, 1H), 1.51 (s, 9H).

¹³C NMR (101 MHz, DMSO-d₆): 155.1 (d, *J* = 28.0 Hz), 147.5, 147.1, 139.1 (d, *J* = 229.3 Hz), 127.4 (d, *J* = 38.0 Hz), 86.6, 27.0.

HRESI-MS: calculated for (C₉H₁₁FN₂O₄, M+Na), 253.0601; found 253.0611.




tert-butyl 5-fluoro-2,6-dioxo-3-(tetrahydrofuran-2-yl)-3,6-dihydropyrimidine-1(2H)-carboxylate (10b)

Isolated by gradient elution from the column with hexane-EtOAc (10:1 to 5:2) in 81 % yield as a white solid.

¹H NMR (400 MHz, CDCl₃): 7.42 (d, *J* = 6.12 Hz, 1H), 5.97-5.95 (m, 1H), 4.27-4.22 (m, 1H), 4.04-3.98 (m, 1H), 2.47-2.37 (m, 1H), 2.18-2.05 (m, 2H), 1.97-1.90 (m, 1H), 1.62 (s, 9H)

¹³C NMR (101 MHz, CDCl₃): 154.8 (d, *J* = 28.0 Hz), 146.8, 146.7, 139.9 (d, *J* = 238.0 Hz), 123.2 (d, *J* = 34.2 Hz), 88.2, 87.8, 70.6, 33.1, 27.5, 23.8.

HRESI-MS: calculated for (C₁₃H₁₇FN₂O₅, M+Na), 323.1019; found 323.1012.




5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (Tegafur)

N3-Boc-N1-tetrahydrofuranyl-5-fluorouracil (**10b**) (60 mg, 0.2 mmol) was heated to 75°C in 2 mL of isopropanol for 4h. The evaporation of the solvent under reduced pressure gave 5-fluoro-1-(tetrahydro-2-furyl)-2,4(1H,3H)-pyrimidinedione in quantitative yield (40 mg).

¹H NMR (400 MHz, DMSO-d₆): 11.77 (br, 1H), 7.87 (d, *J* = 6.96 Hz, 1H), 5.90-5.88 (m, 1H), 4.24-4.19 (m, 1H), 3.81-3.75 (m, 1H), 2.25-2.17 (m, 1H), 2.03-1.87 (m, 3H)

¹³C NMR (101 MHz, DMSO-d₆): 157.2 (d, *J* = 26.3 Hz), 148.9, 139.9 (d, *J* = 231.0 Hz), 125.0 (d, *J* = 34.0 Hz), 86.3, 69.3, 31.5, 23.7.




tert-butyl 5-fluoro-2,6-dioxo-3-(tetrahydro-2H-pyran-2-yl)-3,6-dihydropyrimidine-1(2H)-carboxylate (10c)

¹H NMR (400 MHz, CDCl₃): 7.50 (d, *J* = 6.1 Hz, 1H), 5.55-5.51 (m, 1H), 4.16-4.12 (m, 1H), 3.69-3.62 (m, 1H), 2.02-1.94 (m, 2H), 1.63-1.57 (m, 2H), 1.61 (s, 9H), 1.51-1.41 (m, 2H).

¹³C NMR (101 MHz, CDCl₃): 154.6 (d, *J* = 28 Hz), 146.9, 146.7, 140.2 (d, *J* = 239 Hz), 123.8 (d, *J* = 34 Hz), 87.8, 83.1, 69.4, 31.2, 27.6, 24.9, 22.6.

HRESI-MS: calculated for (C₁₃H₁₇FN₂O₆, M+Na), 337.1176; found 337.1171.




tert-butyl 3-(1,4-dioxan-2-yl)-5-fluoro-2,6-dioxo-3,6-dihydropyrimidine-1(2H)-carboxylate (10d)

¹H NMR (400 MHz, CDCl₃): 7.64 (d, *J* = 6.0 Hz, 1H), 5.72-5.70 (m, 1H), 4.03-3.99 (m, 2H), 3.95-3.90 (m, 1H), 3.81-3.77 (m, 1H), 3.70-3.63 (m, 1H), 3.43-3.38 (m, 1H), 1.60 (s, 9H).

¹³C NMR (101 MHz, CDCl₃): 154.4 (d, *J* = 28 Hz), 146.9, 146.4, 140.1 (d, *J* = 238 Hz), 123.9 (d, *J* = 35 Hz), 88.1, 78.9, 68.2, 66.8, 65.8, 27.5.

HRESI-MS: calculated for (C₁₃H₁₇FN₂O₆, M+Na), 339.0968; found 339.0978.



tert-butyl 3-(1,2-dimethoxyethyl)-5-fluoro-2,6-dioxo-3,6-dihydropyrimidine-1(2H)-carboxylate (10e)

Isolated by gradient elution from the column with hexane/EtOAc as eluent (10:1) in 44 % yield as a colorless oil.

¹H NMR (400 MHz, CDCl₃): 7.47 (d, *J* = 5.8 Hz, 1H), 5.69-5.67 (m, 1H), 3.60-3.58 (m, 2H), 3.42 (s, 3H), 3.40 (s, 3H), 1.62 (s, 9H).

¹³C NMR (101 MHz, CDCl₃): 154.7 (d, *J* = 27 Hz), 147.9, 146.7, 140.3 (d, *J* = 240 Hz), 123.7 (d, *J* = 33.5 Hz), 88.0, 85.4, 72.4, 59.9, 57.6, 27.6.


HRESI-MS: calculated for (C₁₃H₁₉FN₂O₆, M+Na), 341.1125; found 341.1120.

8. References


- [1] Tamaru, Y.; Hojo, M.; Higashimura, H.; Yoshida, Z. I., *J. Am. Chem. Soc.* **1988**, *110*, 3994-4002.
- [2] Zhang, G.; Cui, L.; Wang, Y.; Zhang, L., *J. Am. Chem. Soc.*, **2010**, *132*, 1474-1475.
- [3] Barluenga, J.; Álvarez-Gutiérrez, J. M.; Ballesteros, A.; González, J. M., *Angew. Chem. Int. E.*, **2007**, *46*, 1281-1283.
- [4] Guzman, A.; Jaime-Figueroa, S.; Morgans, D.J.; Zamilpa, A., *Synth. Comm.*, **2001**, *31*, 3739 - 3746.
- [5] Jacobsen, M. F.; Knudsen, M. M.; Gothelf, K. V., *J. Org. Chem.*, **2006**, *71*, 9183.
- [6] Pan, S.; Liu, J.; Li, H.; Wang, Z.; Guo, X.; Li, Z. *Org. Lett.* **2010**, *12*, 1932-1935.

9. NMR Spectra


^1H and ^{13}C NMR spectra of N-benzyl-N-(tetrahydrofuran-2-yl)methanesulfonamide (3a)




^1H and ^{13}C NMR spectra of N-cyclohexyl-N-(tetrahydrofuran-2-yl)methanesulfonamide (3b)





^1H and ^{13}C NMR spectra of N-(tert-butyl)-N-(tetrahydrofuran-2-yl)methanesulfonamide (3c)




^1H and ^{13}C NMR of N-(2,2-dimethylpent-4-en-1-yl)-N-(tetrahydrofuran-2-yl)methanesulfonamide (3d)





¹H and ¹³C NMR of N-allyl-N-(tetrahydrofuran-2-yl)methanesulfonamide (3e)




^1H and ^{13}C NMR of N-(1-phenylethyl)-N-(tetrahydrofuran-2-yl)methanesulfonamide (d.r. 2:3) major isomer (3f)




¹H and ¹³C NMR of N-(1-phenylethyl)-N-(tetrahydrofuran-2-yl)methanesulfonamide (d.r. 2:3) minor isomer (3g)




^1H and ^{13}C NMR spectra of N-phenyl-N-(tetrahydrofuran-2-yl)methanesulfonamide (3h)




¹H and ¹³C NMR spectra of N-hexyl-4-methyl-N-(tetrahydrofuran-2-yl)benzenesulfonamide (3i)





¹H and ¹³C NMR spectra of N-cyclohexyl-4-methyl-N-(tetrahydrofuran-2-yl)benzenesulfonamide (3j)





¹H and ¹³C NMR spectra of N-isopropyl-4-methyl-N-(tetrahydrofuran-2-yl)benzenesulfonamide (3k)





^1H and ^{13}C NMR spectra of N-allyl-4-methyl-N-(tetrahydrofuran-2-yl)benzenesulfonamide (**8** (**3l**))




¹H and ¹³C NMR spectra of N-(2,2-dimethylpent-4-en-1-yl)-4-methyl-N-(tetrahydrofuran-2-yl)benzenesulfonamide 2 (3m)




¹H and ¹³C NMR spectra of N-benzyl-4-methyl-N-(tetrahydrofuran-2-yl)benzenesulfonamide (3n)




^1H and ^{13}C NMR spectra of N-(2,2-dimethylpent-4-en-1-yl)-N-(tetrahydrofuran-2-yl)acetamide (5a)




¹H and ¹³C NMR spectra of N-allyl-N-(tetrahydrofuran-2-yl)acetamide (5b)




¹H and ¹³C NMR spectra of N-benzyl-N-(tetrahydrofuran-2-yl)acetamide (5c)




¹H and ¹³C NMR spectra of N-phenyl-N-(tetrahydrofuran-2-yl)acetamide (5d)





¹H and ¹³C NMR spectra of 2,2,2-trifluoro-N-hexyl-N-(tetrahydrofuran-2-yl)acetamide (5e)




¹H and ¹³C NMR spectra of N-(tert-butyl)-2,2,2-trifluoro-N-(tetrahydrofuran-2-yl)acetamide (5f)





¹H and ¹³C NMR spectra of N-allyl-2,2,2-trifluoro-N-(tetrahydrofuran-2-yl)acetamide (5g)




¹H and ¹³C NMR spectra of N-benzyl-2,2,2-trifluoro-N-(tetrahydrofuran-2-yl)acetamide (5h)





¹H and ¹³C NMR spectra of ethyl-4-(N-(tetrahydrofuran-2-yl)acetamido)benzoate (5i)




¹H and ¹³C NMR spectra of N-(4-cyanophenyl)-N-(tetrahydrofuran-2-yl)acetamide (5j)




¹H and ¹³C NMR spectra of N-(tetrahydrofuran-2-yl)-N-(4-(trifluoromethyl)phenyl)acetamide (5k)





¹H and ¹³C NMR spectra of N-(4-bromophenyl)-N-(tetrahydrofuran-2-yl)acetamide (5l)





¹H and ¹³C NMR spectra of N-(4-iodophenyl)-N-(tetrahydrofuran-2-yl)acetamide (5m)




¹H and ¹³C NMR spectra of N-(4-methoxyphenyl)-N-(tetrahydrofuran-2-yl)acetamide (5n)





¹H and ¹³C NMR spectra of N-(6-methylpyridin-2-yl)-N-(tetrahydrofuran-2-yl)acetamide (5o)





^1H and ^{13}C NMR spectra of 2-(tetrahydrofuran-2-yl)isoindoline-1,3-dione (5p)





¹H NMR spectra of 1-(Tetrahydrofuran-2-yl)-1*H*-imidazole 7(a) and 1-(Tetrahydrofuran-2-yl)-1*H*-benzo[d]imidazole (7b)




¹H and ¹³C NMR spectra of N-[Tetrahydrofuran-2-yl]-1H-indole (7c)





¹H and ¹³C NMR spectra of 9-(tetrahydrofuran-2-yl)-9H-carbazole (7d)




¹H and ¹³C NMR spectra of N-benzyl-N-(1,4-dioxan-2-yl)methanesulfonamide (8a)




¹H and ¹³C NMR spectra of 2-(1,4-dioxan-2-yl)isoindoline-1,3-dione (8b)




¹H and ¹³C NMR spectra of N-benzyl-N-(tetrahydro-2H-pyran-2-yl)methanesulfonamide (8c)





¹H and ¹³C NMR spectra of 2-(tetrahydro-2H-pyran-2-yl)isoindoline-1,3-dione (8d)




¹H and ¹³C NMR spectra of N-allyl-N-(5-methyltetrahydrofuran-2-yl)methanesulfonamide (8e)




¹H and ¹³C NMR spectra of N-benzyl-N-(1,2-dimethoxyethyl)methanesulfonamide (8f)





¹H and ¹³C NMR spectra of N-benzyl-N-(1,2-dimethoxyethyl)-2,2,2-trifluoroacetamide (8g)




¹H and ¹³C NMR spectra of N-benzyl-2,2,2-trifluoro-N-((2-methoxyethoxy)methyl)acetamide (8g')





¹H and ¹³C NMR spectra of N-allyl-N-(1,2-dimethoxyethyl)methanesulfonamide (8h)





¹H and ¹³C NMR spectra of 3-(4-methoxybenzyl)-5-methylpyrimidine-2,4(1H,3H)-dione (9a)




¹H and ¹³C NMR spectra of 3-(4-methoxybenzyl)-5-methyl-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (10a)




¹H and ¹³C NMR spectra of di-tert-butyl 5-fluoro-2,4-dioxypyrimidine-1,3(2H,4H)-dicarboxylate (9b')




¹H and ¹³C NMR spectra of tert-butyl 5-fluoro-2,6-dioxo-3,6-dihydropyrimidine-1(2H)-carboxylate (9b)




¹H and ¹³C NMR spectra of tert-butyl-5-fluoro-2,6-dioxo-3-(tetrahydrofuran-2-yl)-3,6-dihydropyrimidine-1(2H)-carboxylate (10b)




¹H and ¹³C NMR spectra of 5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione



¹H and ¹³C NMR spectra of tert-butyl 5-fluoro-2,6-dioxo-3-(tetrahydro-2H-pyran-2-yl)-3,6-dihydropyrimidine-1(2H)-carboxylate (10c)



¹H and ¹³C NMR spectra of tert-butyl 3-(1,4-dioxan-2-yl)-5-fluoro-2,6-dioxo-3,6-dihydropyrimidine-1(2H)-carboxylate (10d)



¹H and ¹³C NMR spectra of tert-butyl 3-(1,2-dimethoxyethyl)-5-fluoro-2,6-dioxo-3,6-dihydropyrimidine-1(2H)-carboxylate (10e)

